Manulife Extends Strategic Partnership with CUHK Medical Centre to Include Histotripsy in its Holistic "Medical Professional Support Service"

APAC - English

• APAC - Traditional Chinese

Histotripsy is an FDA-approved technology that offers liver cancer patients a non-invasive, painless, and highly effective treatment option

HONG KONG, March 7, 2025 /PRNewswire/ -- Manulife announced today the extension of its strategic partnership with CUHK Medical Centre (CUHKMC), originally established in 2021, as part of its commitment to enhancing access to quality healthcare for its customers. Manulife is pleased to share that, through its Holistic "Medical Professional Support Service" for specified medical insurance plan^[1] customers diagnosed with cancer or suspected of having cancer, it will incorporate histotripsy as a treatment option, once this treatment becomes publicly available at CUHKMC, and patients would be enrolled in clinical trials for close monitoring and evaluation of the clinical outcome.

Liver cancer is the fifth most common cancer in Hong Kong, making up 4.6% of all new cancer cases in 2022.^[2] Histotripsy is an FDA-approved technology that offers liver cancer patients a non-invasive, painless, and highly effective treatment option.^[3] Earlier, this treatment was introduced to medical institutions in Hong Kong through donations from the Li Ka Shing Foundation. ^[3]

"This extended partnership highlights Manulife's commitment to being a pioneering health insurance provider in Hong Kong, supporting our customers throughout their health journeys and helping to protect more lives," said Carrie Tong, Chief Operations Officer of Manulife Hong Kong and Macau.

All Manulife medical plan customers are eligible for coverage of this innovative and FDA-approved histotripsy treatment, further underscoring Manulife's dedication to enhancing the quality of healthcare accessible to customers.

Manulife established a strategic partnership with CUHKMC in 2021, providing eligible customers with priority access to the hospital's oncologists for a one-time, free independent medical consultation. In 2023, this partnership was expanded to offer a cashless pre-approval service for over 300 all-inclusive hospital packages, including endoscopic and surgical procedures provided by CUHKMC.

About Manulife Hong Kong 
Manulife Hong Kong has been a trusted name for more than 125 years. Since our operations started in Asia in 1897, we have grown to become one of the top-tier providers of financial services, offering a diverse range of protection and wealth products and services to over 2.6 million customers in Hong Kong and Macau. We are committed to helping make decisions easier and lives better for our customers.

Manulife Hong Kong, through Manulife International Holdings Limited, owns Manulife (International) Limited, Manulife Investment Management (Hong Kong) Limited, and Manulife Provident Funds Trust Company Limited. These entities are all subsidiaries of Manulife Financial Corporation.

About Manulife 
Manulife Financial Corporation is a leading international financial services provider, helping our customers make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we operate as Manulife across Canada, Asia, and Europe, and primarily as John Hancock in the United States, providing financial advice and insurance for individuals, groups and businesses. Through Manulife Wealth & Asset Management, we offer global investment, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2024, we had more than 37,000 employees, over 109,000 agents, and thousands of distribution partners, serving over 36 million customers. We trade as 'MFC' on the Toronto, New York, and the Philippine stock exchanges, and under '945' in Hong Kong.

Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com.

SOURCE Manulife Hong Kong